evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,018 questions · 3,100 findings · 369 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 774 · 25%GRADE not reported 108 · 3.5%Very low 727 · 23.5%Low 840 · 27.1%Moderate 474 · 15.3%High 177 · 5.7%

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

BPD or death by it prior to 37 weeks' PMA (outcomes collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in BPD or death by it prior to 37 weeks' PMA (outcomes collected… compared with placebo (high certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Severe (grade 3 or greater) intraventricular hemorrhage (IVH) on cranial ultrasound ‐ not reported · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in severe IVH (grade 3 or 4) compared with placebo (moderate certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Any late‐onset sepsis ‐ all infants · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in late‐onset sepsis (> 72 hours of age) compared with placebo (high certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Necrotizing enterocolitis (suspected or proven) · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in suspected or proven NEC compared with placebo (high certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Type 1 ROP or death before determination of ROP outcome using the adjudicated ROP outcome · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in type 1 ROP or death before determination of ROP outcome using the… compared with placebo (moderate certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Type 1 ROP including adjudicated ROP outcome · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in type 1 ROP including adjudicated ROP outcome compared with placebo (moderate certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

All‐cause mortality (outcome collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in all‐cause mortality (outcome collected through first event: death,… compared with placebo (moderate certainty).

1 finding from 1 review

Intervention not reported

Incidence of overt retinopathya,b · people with type 2 diabetes

The intervention showed no clear difference in incidence of overt retinopathya,b (moderate certainty).

1 finding from 1 review

Alitretinoin vs placebo

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Alitretinoin vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review